<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03783195</url>
  </required_header>
  <id_info>
    <org_study_id>17-3348</org_study_id>
    <secondary_id>P30DK056336-16S1</secondary_id>
    <nct_id>NCT03783195</nct_id>
  </id_info>
  <brief_title>Genetic-specific Effects of Fructose on Liver Lipogenesis</brief_title>
  <official_title>Genetic-specific Effects of Fructose on Liver Lipogenesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to identify a set of genotypes that increase the risk for
      nonalcoholic fatty liver disease (NAFLD) and predispose individuals to increased de novo
      lipogenesis (DNL) and liver fat accumulation when exposed to fructose intake. The proposed
      goal will be achieved through the completion of following aims:

        1. To determine the impact of prolonged exposure of fructose on hepatic lipid accumulation
           in Caucasian individuals with high and low genetic risk for NAFLD,

        2. to determine the impact of acute exposure of fructose on hepatic DNL, and

        3. to determine the relationship between markers of DNL, liver fat accumulation and serum
           concentrations of lipids, uric acid and liver function markers before and after the
           fructose challenge.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND AND RATIONALE Non-alcoholic fatty liver disease (NAFLD) is characterized by fat
      accumulation in liver cells not caused by alcohol. A leading cause of chronic liver disease
      in the US, NAFLD represents a group of disorders including steatosis, nonalcoholic
      steatohepatitis with fibrosis. It has substantially risen in prevalence over the last two
      decades with the estimated prevalence being 20% among US adults and 25% in young adults
      (18-39 years). Over 64 million individuals are believed to have NAFLD with annual medical
      costs rising to more $100 billion. More common in individuals who are obese or diabetic
      and/or have metabolic syndrome, NAFLD has been associated with increased cirrhosis,
      liver-related mortality and hepatocellular carcinoma.

      Both genetic and environmental, including nutritional, factors contribute to the onset and
      progression of NAFLD. Increased consumption of sugar-sweetened, fructose-rich beverages has
      been linked to NAFLD. Fructose, commonly found in soft drinks, fruit juices and energy
      drinks, affects many metabolic processes, foremost being an increase in fat accumulation in
      the liver and hence, NAFLD. Genome-wide and candidate gene studies have identified several
      genes associated with NAFLD. However, none of these studies have shown the cumulative effects
      of single nucleotide polymorphisms (SNPs) on changes in liver fat when exposed to fructose.
      The results from this study can be extrapolated to larger cohorts and other ethnicities and
      are therefore, expected to lay the foundation for developing personalized nutritional plans.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to high genetic risk score group in parallel to low genetic risk score group</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in liver fat content from baseline to week 3</measure>
    <time_frame>at week 0 and 3</time_frame>
    <description>Magnetic resonance imaging (MRI) and transient elastography (Fibroscan) will be used to measure percent changes in liver fat.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline in very low density lipoprotein-triglycerides (VLDL-TG) production rate.</measure>
    <time_frame>0, 1 and 3 hours at week 0 and week 3</time_frame>
    <description>VLDL-TG production rate is a measure of liver secretion of VLDL-TG per liter of plasma per minute (umol/L/min).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to week 3 in serum concentrations of triglycerides</measure>
    <time_frame>at week 0 and week 3</time_frame>
    <description>Fasting concentrations of serum triglycerides (mg/dl) will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to week 3 in serum concentrations of HDL cholesterol</measure>
    <time_frame>at week 0 and week 3</time_frame>
    <description>Fasting concentrations of serum HDL cholesterol (mg/dl) will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to week 3 in serum concentrations of LDL cholesterol</measure>
    <time_frame>at week 0 and week 3</time_frame>
    <description>Fasting concentrations of serum LDL cholesterol (mg/dl) will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent change from baseline to week 3 in serum concentrations of total cholesterol</measure>
    <time_frame>at week 0 and week 3</time_frame>
    <description>Fasting serum concentrations of total cholesterol (mg/dl) will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to week 3 in serum concentrations of uric acid</measure>
    <time_frame>at week 0 and week 3</time_frame>
    <description>Fasting concentrations of serum uric acid (ng/ml) will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to week 3 in serum concentrations of liver function marker (Alanine transaminase- ALT).</measure>
    <time_frame>at week 0 and week 3</time_frame>
    <description>Fasting concentrations of serum ALT (IU/L) will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to week 3 in serum concentrations of liver function marker (Aspartate transaminase-AST).</measure>
    <time_frame>at week 0 and week 3</time_frame>
    <description>Fasting concentrations of serum AST (IU/L) will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to week 3 in serum concentrations of liver function marker (Alkaline phosphatase-ALP)</measure>
    <time_frame>at week 0 and week 3</time_frame>
    <description>Fasting concentrations of serum ALP (IU/L) will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to week 3 in serum concentrations of liver function marker (Gamma glutamyl transpeptidase-GGT)</measure>
    <time_frame>at week 0 and week 3</time_frame>
    <description>Fasting concentrations of serum GGT will be measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>NAFLD</condition>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>High GRS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group consists of individuals who are in the highest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low GRS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This groups consists of individuals who are in the lowest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sugar drink</intervention_name>
    <description>A sugar drink made with 1.2 g/kg body weight of added sugar( 0.75g/kg body weight of fructose + 0.45g/kg body weight of glucose) and 24oz water</description>
    <arm_group_label>High GRS group</arm_group_label>
    <arm_group_label>Low GRS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects 12 - 40 years

          2. No history of alcohol abuse (&gt; 7 drinks per week)

          3. History of fructose intake of &lt; 14 drinks per week

          4. Caucasian ethnicity

          5. BMI &gt; 25kg/m² - 32kg/m² or 85th -99th percentile but otherwise healthy

        Exclusion Criteria:

          1. ages &lt; 12 and &gt; 40 years

          2. Pregnant/lactating

          3. known alcohol abuse or fructose intake &gt; 14 drinks per week

          4. not of Caucasian ethnicity

          5. glucose levels &gt; 100 mg/dL if fasting, &gt; 140mg/dL if within 2 hours post meal and &gt;
             200 mg/dL if random sample

          6. taking anti-hypertensive, anti-diabetic, uric acid and/or lipid-lowering medications

          7. known diagnosis of diabetes, fructose intolerance, chronic kidney disease, NAFLD or
             any liver-related disease, hypertriglyceridemia, polycystic ovary syndrome,
             hypothyroidism, obstructive sleep apnea, hypopituitarism and hypogonadism

          8. BMI &lt; 25kg/m² or &gt; 32 kg/m² or &lt; 85th or &gt; 99th percentile

          9. Liver fat fraction &gt;5% as per baseline MRI scan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saroja Voruganti</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saroja Voruganti, PhD</last_name>
    <phone>704-250-5009</phone>
    <email>saroja@unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chinmayee Panda, PhD</last_name>
    <phone>704-250-5060</phone>
    <email>chinmayee_panda@unc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UNC Nutrition Research Institute</name>
      <address>
        <city>Kannapolis</city>
        <state>North Carolina</state>
        <zip>28081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saroja Voruganti</last_name>
      <phone>704-250-5009</phone>
      <phone_ext>7042505009</phone_ext>
      <email>saroja@unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brea Correll</last_name>
      <phone>7042505055</phone>
      <email>brea_correll@unc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, Racila A, Hunt S, Beckerman R. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016 Nov;64(5):1577-1586. doi: 10.1002/hep.28785. Epub 2016 Sep 26.</citation>
    <PMID>27543837</PMID>
  </reference>
  <reference>
    <citation>Vos MB, Kimmons JE, Gillespie C, Welsh J, Blanck HM. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med. 2008 Jul 9;10(7):160.</citation>
    <PMID>18769702</PMID>
  </reference>
  <reference>
    <citation>Moore JB, Gunn PJ, Fielding BA. The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. Nutrients. 2014 Dec 10;6(12):5679-703. doi: 10.3390/nu6125679. Review.</citation>
    <PMID>25514388</PMID>
  </reference>
  <reference>
    <citation>Faeh D, Minehira K, Schwarz JM, Periasamy R, Park S, Tappy L. Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes. 2005 Jul;54(7):1907-13. Erratum in: Diabetes. 2006 Feb;55(2):563. Periasami, Raj [corrected to Periasamy, Raj]; Seongsu, Park [corrected to Park, Seongsu].</citation>
    <PMID>15983189</PMID>
  </reference>
  <reference>
    <citation>Alwahsh SM, Gebhardt R. Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD). Arch Toxicol. 2017 Apr;91(4):1545-1563. doi: 10.1007/s00204-016-1892-7. Epub 2016 Dec 19. Review.</citation>
    <PMID>27995280</PMID>
  </reference>
  <reference>
    <citation>Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano T, Beysen C, Hellerstein MK, Berglund L, Havel PJ. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009 May;119(5):1322-34. doi: 10.1172/JCI37385. Epub 2009 Apr 20.</citation>
    <PMID>19381015</PMID>
  </reference>
  <reference>
    <citation>Stanhope KL, Medici V, Bremer AA, Lee V, Lam HD, Nunez MV, Chen GX, Keim NL, Havel PJ. A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. Am J Clin Nutr. 2015 Jun;101(6):1144-54. doi: 10.3945/ajcn.114.100461. Epub 2015 Apr 22.</citation>
    <PMID>25904601</PMID>
  </reference>
  <reference>
    <citation>Softic S, Gupta MK, Wang GX, Fujisaka S, O'Neill BT, Rao TN, Willoughby J, Harbison C, Fitzgerald K, Ilkayeva O, Newgard CB, Cohen DE, Kahn CR. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. J Clin Invest. 2017 Nov 1;127(11):4059-4074. doi: 10.1172/JCI94585. Epub 2017 Oct 3. Erratum in: J Clin Invest. 2018 Mar 1;128(3):1199.</citation>
    <PMID>28972537</PMID>
  </reference>
  <reference>
    <citation>Basaranoglu M, Basaranoglu G, Bugianesi E. Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr. 2015 Apr;4(2):109-16. doi: 10.3978/j.issn.2304-3881.2014.11.05. Review.</citation>
    <PMID>26005677</PMID>
  </reference>
  <reference>
    <citation>Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram S, Le M, Ishimoto T, Sautin YY, Lanaspa MA. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013 Oct;62(10):3307-15. doi: 10.2337/db12-1814. Review.</citation>
    <PMID>24065788</PMID>
  </reference>
  <reference>
    <citation>Zhou Y, Wei F, Fan Y. High serum uric acid and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Clin Biochem. 2016 May;49(7-8):636-42. doi: 10.1016/j.clinbiochem.2015.12.010. Epub 2015 Dec 29. Review.</citation>
    <PMID>26738417</PMID>
  </reference>
  <reference>
    <citation>Goran MI, Walker R, Allayee H. Genetic-related and carbohydrate-related factors affecting liver fat accumulation. Curr Opin Clin Nutr Metab Care. 2012 Jul;15(4):392-6. doi: 10.1097/MCO.0b013e3283544477. Review.</citation>
    <PMID>22617559</PMID>
  </reference>
  <reference>
    <citation>Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, Eiriksdottir G, Garcia ME, Launer LJ, Nalls MA, Clark JM, Mitchell BD, Shuldiner AR, Butler JL, Tomas M, Hoffmann U, Hwang SJ, Massaro JM, O'Donnell CJ, Sahani DV, Salomaa V, Schadt EE, Schwartz SM, Siscovick DS; NASH CRN; GIANT Consortium; MAGIC Investigators, Voight BF, Carr JJ, Feitosa MF, Harris TB, Fox CS, Smith AV, Kao WH, Hirschhorn JN, Borecki IB; GOLD Consortium. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011 Mar;7(3):e1001324. doi: 10.1371/journal.pgen.1001324. Epub 2011 Mar 10.</citation>
    <PMID>21423719</PMID>
  </reference>
  <reference>
    <citation>Davis JN, Lê KA, Walker RW, Vikman S, Spruijt-Metz D, Weigensberg MJ, Allayee H, Goran MI. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr. 2010 Dec;92(6):1522-7. doi: 10.3945/ajcn.2010.30185. Epub 2010 Oct 20.</citation>
    <PMID>20962157</PMID>
  </reference>
  <reference>
    <citation>Santoro N, Caprio S, Pierpont B, Van Name M, Savoye M, Parks EJ. Hepatic De Novo Lipogenesis in Obese Youth Is Modulated by a Common Variant in the GCKR Gene. J Clin Endocrinol Metab. 2015 Aug;100(8):E1125-32. doi: 10.1210/jc.2015-1587. Epub 2015 Jun 4. Erratum in: J Clin Endocrinol Metab. 2020 Jan 2;105(2):.</citation>
    <PMID>26043229</PMID>
  </reference>
  <reference>
    <citation>Ter Horst KW, Schene MR, Holman R, Romijn JA, Serlie MJ. Effect of fructose consumption on insulin sensitivity in nondiabetic subjects: a systematic review and meta-analysis of diet-intervention trials. Am J Clin Nutr. 2016 Dec;104(6):1562-1576. Epub 2016 Nov 9. Review.</citation>
    <PMID>27935520</PMID>
  </reference>
  <reference>
    <citation>Schwarz JM, Noworolski SM, Erkin-Cakmak A, Korn NJ, Wen MJ, Tai VW, Jones GM, Palii SP, Velasco-Alin M, Pan K, Patterson BW, Gugliucci A, Lustig RH, Mulligan K. Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity. Gastroenterology. 2017 Sep;153(3):743-752. doi: 10.1053/j.gastro.2017.05.043. Epub 2017 Jun 1.</citation>
    <PMID>28579536</PMID>
  </reference>
  <reference>
    <citation>Stanhope KL, Bremer AA, Medici V, Nakajima K, Ito Y, Nakano T, Chen G, Fong TH, Lee V, Menorca RI, Keim NL, Havel PJ. Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. J Clin Endocrinol Metab. 2011 Oct;96(10):E1596-605. doi: 10.1210/jc.2011-1251. Epub 2011 Aug 17.</citation>
    <PMID>21849529</PMID>
  </reference>
  <reference>
    <citation>Schwarz JM, Noworolski SM, Wen MJ, Dyachenko A, Prior JL, Weinberg ME, Herraiz LA, Tai VW, Bergeron N, Bersot TP, Rao MN, Schambelan M, Mulligan K. Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat. J Clin Endocrinol Metab. 2015 Jun;100(6):2434-42. doi: 10.1210/jc.2014-3678. Epub 2015 Mar 31.</citation>
    <PMID>25825943</PMID>
  </reference>
  <reference>
    <citation>Ventura EE, Davis JN, Goran MI. Sugar content of popular sweetened beverages based on objective laboratory analysis: focus on fructose content. Obesity (Silver Spring). 2011 Apr;19(4):868-74. doi: 10.1038/oby.2010.255. Epub 2010 Oct 14.</citation>
    <PMID>20948525</PMID>
  </reference>
  <reference>
    <citation>Akhavan T, Anderson GH. Effects of glucose-to-fructose ratios in solutions on subjective satiety, food intake, and satiety hormones in young men. Am J Clin Nutr. 2007 Nov;86(5):1354-63.</citation>
    <PMID>17991646</PMID>
  </reference>
  <reference>
    <citation>Faix D, Neese R, Kletke C, Wolden S, Cesar D, Coutlangus M, Shackleton CH, Hellerstein MK. Quantification of menstrual and diurnal periodicities in rates of cholesterol and fat synthesis in humans. J Lipid Res. 1993 Dec;34(12):2063-75.</citation>
    <PMID>8301227</PMID>
  </reference>
  <reference>
    <citation>Hudgins LC, Parker TS, Levine DM, Hellerstein MK. A dual sugar challenge test for lipogenic sensitivity to dietary fructose. J Clin Endocrinol Metab. 2011 Mar;96(3):861-8. doi: 10.1210/jc.2010-2007. Epub 2011 Jan 20.</citation>
    <PMID>21252253</PMID>
  </reference>
  <reference>
    <citation>Awai HI, Newton KP, Sirlin CB, Behling C, Schwimmer JB. Evidence and recommendations for imaging liver fat in children, based on systematic review. Clin Gastroenterol Hepatol. 2014 May;12(5):765-73. doi: 10.1016/j.cgh.2013.09.050. Epub 2013 Sep 30. Review.</citation>
    <PMID>24090729</PMID>
  </reference>
  <reference>
    <citation>Shin HJ, Kim HG, Kim MJ, Koh H, Kim HY, Roh YH, Lee MJ. Normal range of hepatic fat fraction on dual- and triple-echo fat quantification MR in children. PLoS One. 2015 Feb 6;10(2):e0117480. doi: 10.1371/journal.pone.0117480. eCollection 2015.</citation>
    <PMID>25659155</PMID>
  </reference>
  <reference>
    <citation>Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep. 2014 Feb;16(2):372. doi: 10.1007/s11894-014-0372-6. Review.</citation>
    <PMID>24452634</PMID>
  </reference>
  <reference>
    <citation>Lallukka S, Sädevirta S, Kallio MT, Luukkonen PK, Zhou Y, Hakkarainen A, Lundbom N, Orho-Melander M, Yki-Järvinen H. Predictors of Liver Fat and Stiffness in Non-Alcoholic Fatty Liver Disease (NAFLD) - an 11-Year Prospective Study. Sci Rep. 2017 Nov 6;7(1):14561. doi: 10.1038/s41598-017-14706-0.</citation>
    <PMID>29109528</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 17, 2018</study_first_submitted>
  <study_first_submitted_qc>December 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2018</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucose</keyword>
  <keyword>Fructose</keyword>
  <keyword>Fatty-liver</keyword>
  <keyword>Polymorphisms</keyword>
  <keyword>Imaging</keyword>
  <keyword>Fibroscan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with University of North Carolina (UNC).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>9- 36 months following article publication</ipd_time_frame>
    <ipd_access_criteria>Investigators whose proposed use of the data has been approved by the institutional review board, independent ethics committee or research ethics committee, as applicable and an executed data use agreement with UNC.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

